Condition: Advanced Neuroendocrine Carcinoma · Sponsor: Nanjing Leads Biolabs Co.,Ltd
An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
This description comes directly from the study's public registry record.
lin shen · 025-83378099 · kongxue@leadsbiolabs.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| Anhui Cancer Hospital | Hefei, Anhui, China | Recruiting |
| Beijing GoBroad Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06157827